Biologics News
GOMEKLI FDA Approved for Treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), Available at Biologics by McKesson
CARY, N.C., FEBRUARY 18, 2025—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been
Romvimza (vimseltinib), FDA Approved for Treatment of Tenosynovial Giant Cell Tumor (TGCT), Available at Biologics by McKesson
CARY, N.C., February 17, 2025—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been
REVUFORJ (revumenib), FDA Approved for Treatment of Patients with Acute Myeloid Leukemia and Acute Lymphoid Leukemia, Available at Biologics by McKesson
CARY, N.C., January 24, 2025—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected
Danziten (nilotinib), FDA Approved for Treatment of Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Available at Biologics by McKesson
CARY, N.C., December 6, 2024—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been
InspiroGene by McKesson Partners with Vertex to Expand Distribution Options for CASGEVY® (exagamglogene autotemcel)
CARY, N.C., November 14, 2024—We are thrilled to announce a pivotal milestone for Biologics. As of today, we’ve gained access
VORANIGO (vorasidenib), FDA Approved for the Treatment of Patients with IDH-mutant Diffuse Glioma, Available at Biologics by McKesson
CARY, N.C., September 25, 2024—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by